About Ritter Pharmaceuticals, Inc.
Ritter Pharmaceuticals, Inc. develops novel therapeutic products, which modulate the human gut microbiome to treat inflammatory, gastrointestinal and metabolic diseases. Our microbiome modulators provide specialized nutrition that selectively increases the growth of beneficial bacteria in the colonic ecosystem and creates significant improvement in the health of individuals that suffer from these diseases.
Ritter’s leadership team has extensive biotechnology expertise in discovering, developing and commercializing therapeutic products. We have attracted a scientific team comprised of innovative researchers who are world renowned in their knowledge and understanding of the host-microbiome. Combined, our expertise is leading the way in the understanding of the host gut microbiome and the discovery in novel microbiome modulators.
Our lead compound, RP-G28 is currently under development for the treatment of lactose intolerance. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide. The product stimulates the growth of lactose-metabolizing bacteria in the colon, which reduces lactose-derived gas production, and thereby mitigates the symptoms of lactose intolerance in the process.